再発性 GBM 患者における TheraSphere Glioblastoma (GBM) デバイスの安全性を評価するための実現可能性調査 (FRONTIER)
FRONTIER: 再発性 GBM 患者における TheRaSphere GliOblastoma (GBM) デバイスの安全性を評価するための実現可能性調査
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
調査の概要
詳細な説明
Glioblastoma (GBM) is a highly aggressive brain cancer with a grave prognosis, resulting in <7% of patients surviving to five years post-diagnosis. External beam radiotherapy (EBRT) is currently a mainstay treatment for GBM; however, the dose delivered is limited by side effects. The targeted radiotherapy of the TheraSphere GBM Y-90 Glass Microsphere System (TheraSphere GBM) has promising potential to provide GBM patients with reduced side effects compared to external beam radiotherapy as well as a more effective treatment for this catastrophic disease.
The TheraSphere GBM device utilized in the FRONTIER trial is an yttrium-90 (Y-90) glass microsphere therapy for selective internal radiation therapy (endovascular radiotherapy) in recurrent GBM patients. The TheraSphere GBM treatment utilizes intra-arterial delivery and takes advantage of blood flow and direct tumor delivery. Treatment can be delivered by specific placement of a catheter close to the tumor through known angiographic techniques currently utilized by neuro-endovascular or interventional radiology physicians. Angiographic evaluation prior to treatment allows identification of tumor feeding arteries and definition of the treatment volume. TheraSphere GBM could achieve a high tumor response rate based on delivery of a tumor absorbed dose that is not currently possible with EBRT.
In consideration of the potential benefit of a more localized, targeted treatment with a reduced side effect profile compared to other treatment options, and the potential impact on patients' quality of life for this devastating disease, this First-in-Human Early Feasibility Study (EFS) of the TheraSphere GBM Y-90 Glass Microsphere System for the treatment of recurrent GBM is being conducted.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Sally Linda
- 電話番号:952-201-3102
- メール:Sally.Linda@bsci.com
研究連絡先のバックアップ
- 名前:Lilian Liu Pan
- 電話番号:858-888-5682
- メール:Lilian.LiuPan@bsci.com
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- 引きこもった
- University of Alabama Birmingham
-
-
California
-
San Diego、California、アメリカ、92103
- 募集
- University of California San Diego
-
主任研究者:
- Zachary Berman, MD
-
コンタクト:
- Sheila Medina Torne
- 電話番号:858-822-6100
- メール:s4medina@health.ucsd.edu
-
San Francisco、California、アメリカ、94143
- 募集
- University of California San Francisco
-
主任研究者:
- Nicholas Butowski, MD
-
コンタクト:
- Stephanie Lewis
- 電話番号:415-353-2193
- メール:NeuroOncNewPatientCoord@ucsf.edu
-
-
Florida
-
Jacksonville、Florida、アメリカ、32224
- 募集
- Mayo Jacksonville
-
主任研究者:
- Alfredo Quinones-Hinojosa, MD
-
コンタクト:
- Aleeshba Basil
- 電話番号:855-776-0015
- メール:Basil.aleeshba@mayo.edu
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- 募集
- Northwestern Univerity
-
コンタクト:
- Roger Stupp, MD
- 電話番号:866-587-4322
- メール:roger.stupp@northwestern.edu
-
主任研究者:
- Samdeep Mouli, MD
-
コンタクト:
- Emily R Powell
- 電話番号:312-926-3872
- メール:emily.powell@northwestern.edu
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- 引きこもった
- Johns Hopkins Interventional Radiology Center
-
-
Missouri
-
St Louis、Missouri、アメリカ、63130
- 募集
- Washington University School of Medicine
-
コンタクト:
- Rachel Reed
- メール:Rachel.Reed@wustl.edu
-
主任研究者:
- Arindam Chatterjee, M.D.
-
-
New York
-
New York、New York、アメリカ、10075
- 募集
- Lenox Hill Hospital
-
コンタクト:
- Tamika Wong
- 電話番号:212-434-4836
- メール:twong4@northwell.edu
-
主任研究者:
- John Boockvar, MD
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- MD Anderson Cancer Center
-
コンタクト:
- Summer Stovall
- 電話番号:713-745-4243
- メール:SStovall@mdanderson.org
-
主任研究者:
- Stephen Chen, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Subject is 18 years or older and has signed and dated the trial informed consent form (ICF)
-
Life expectancy ≥ 12 weeks
-
Subject is willing and able to comply with the trial testing, procedures, and follow-up schedule
-
History of a histologically confirmed diagnosis of glioblastoma per 2021 WHO criteria
-
Have radiographic evidence of tumor progression/recurrence with measurable disease (≥ 1 cm to ≤ 5cm bidirectional diameters) by contrast-enhancement on MRI, according to RANO criteria
-
Prior surgery and treatment with combination of radiotherapy and chemotherapy ± Tumor Treating Fields (Optune®)
-
Prior cranial radiation dose < 66 Gy
-
WHO performance status ≤ 2
-
The interval since completion of cranial radiotherapy must be > 6 months, unless there is tissue confirmation of tumor recurrence/progression outside the previous radiation treatment field, in which case the interval since completion of cranial radiation must be at least 12 weeks
-
Interval since last systemic therapy until presumed date of intervention ≥ 1 cycle or ≥ 2 biological half-lives, i.e.
- ≥ 4 weeks since last dose of temozolomide
- ≥ 6 weeks since last dose of lomustine or other nitrosourea
- ≥ 2 weeks since last dose of a small molecule targeted agent (Tyrosine Kinase Inhibitor or similar)
- ≥ 6 weeks from last dose of last intravenous bevacizumab infusion, or other antibody-based VEGF therapy
-
If receiving steroids, patient should be on a stable or decreasing dose equivalent to dexamethasone ≤ 6 mg/d, for at least 7 days prior to registration
-
Have adequate organ and bone marrow function within 14 days prior to registration, as defined below:
- INR ≤ 1.2 (in absence of anticoagulation)
- Platelets ≥ 100,000/L
- Creatinine ≤1.5 mg/dL
- Absolute Neutrophil Count ≥1.5 x 10^9/L
- Hemoglobin ≥9.0 g/dL
-
Have a negative pregnancy test within 14 days prior to registration on study (for FOCBP, female of child-bearing potential)
-
Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active must be using, or agree to use, a medically acceptable method of birth control as confirmed by the investigator
-
Angiographic Mapping Inclusion Criteria:
- Accessible neurovascular anatomy that allows for safe microcatheter placement (up to two locations) to infuse TheraSphere GBM to treat all of the T1 enhancing component of target lesion confirmed by neuro-interventional team.
- Total treatment volume is ≤ 150cc as determined by multidisciplinary team.
-
Additional Inclusion Criteria:
- Group A: perfused volume encompasses the non-dominant hemisphere and non-eloquent regions of the brain
- Group B: perfused volume encompasses the non-dominant hemisphere and eloquent regions of the brain
- Group C: perfused volume encompasses the dominant hemisphere and non-eloquent regions of the brain
- Group D: perfused volume encompasses the dominant hemisphere and eloquent regions of the brain
Exclusion Criteria:
-
Have bilateral gadolinium enhancing disease, tumor located in the posterior fossa, tumor involving critical subcortical structures (thalamus/hypothalamus, midbrain, brainstem, corticospinal tract, internal capsule, cerebral peduncle), tumor approximating or invading the brainstem and/or optic chiasma, leptomeningeal disease, or extracranial metastatic disease
-
Have received more than 1 course of prior cranial radiotherapy (EBRT)
-
Have received radiosurgery, brachytherapy, or hypofractionated radiotherapy
-
Have received more than 2 systemic treatment protocols (lines of treatment), not including maintenance temozolomide
-
Have received prior intra-arterial cerebral infusion therapy
-
Have received more than 2 surgical GBM-related procedures
-
Have received prior thoracic radiation therapy
-
Are at increased risk of wound dehiscence by the discretion of the investigators (e.g. brain surgery within the last 3 months, poor skin condition, and/or previously infected surgical field or any other condition that is of increased infectious risk in the opinion of the neurosurgeon)
-
Have uncontrolled epilepsy
-
Have severe and/or insufficiently controlled intercurrent illness; patients with the following are not eligible:
- Hypertension grade 3 or higher without adequate control on medications
- Symptomatic or unstable cardiac disease, known to have right-to-left shunts, or severe pulmonary hypertension (pulmonary artery pressure > 90 mmHg)
- Pulmonary insufficiency (arterial oxygen pressure (Pa,O2) of < 60 mmHg, or oxygen saturation (Sa,O2) of < 90%) as measured by fingertip pulse oximeter
- Ongoing or active bacterial or viral infection requiring systemic treatment (including HIV)
- Pneumonitis
- Psychiatric illness/social situations that would limit compliance with study requirements
- Peripheral Neuropathy ≥ grade 1
- Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety, study endpoints or longevity
-
Are currently pregnant or breast feeding (unless patient agrees to stop breastfeeding)
-
Patients with a history of an active other malignancy within 1 year prior to registration. NOTE: Exceptions to this requirement include adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ without evidence of disease, or recurrent glioblastoma
-
Patients with a history of ischemic cerebral disease and/or at risk of cerebral herniation
-
Medical contraindication to undergo contrast-enhanced magnetic resonance imaging (MRI)
-
Known history of hypersensitivity reactions to iodinated and/or gadolinium-based contrast
-
Subject has received any other investigational agents within 4 weeks of treatment, or is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the Boston Scientific study team)
-
Angiographic Mapping Exclusion Criteria: Patients with significant vascular disease, significant AV shunting, or anatomic tortuosity on MR/CT Angiogram precluding safe or feasible vascular access
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment Group A
Subjects in which the perfused volume encompasses the non-dominant hemisphere and non-eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%. |
Single treatment of TheraSphere GBM device
他の名前:
|
|
実験的:Treatment Group B
Subjects in which the perfused volume encompasses the non-dominant hemisphere and eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%. |
Single treatment of TheraSphere GBM device
他の名前:
|
|
実験的:Treatment Group C
Subjects in which the perfused volume encompasses the dominant hemisphere and non-eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%. |
Single treatment of TheraSphere GBM device
他の名前:
|
|
実験的:Treatment Group D
Subjects in which the perfused volume encompasses the dominant hemisphere and eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%. |
Single treatment of TheraSphere GBM device
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
グレード 3 ~ 5 の非血液毒性の数
時間枠:30日後の索引手順
|
30日後の索引手順
|
|
非標的塞栓術に関連するグレード3以上の中枢神経系毒性の数
時間枠:30日後の索引手順
|
30日後の索引手順
|
|
-医学的または外科的介入を必要とし、病理学によって確認された症候性脳放射線壊死の発生
時間枠:30日後の索引手順
|
30日後の索引手順
|
|
5日以上持続するグレード4の好中球減少症イベントの数
時間枠:30日後の索引手順
|
30日後の索引手順
|
|
グレード4の発熱性好中球減少症の数
時間枠:30日後の索引手順
|
30日後の索引手順
|
|
出血を伴うグレード4の血小板減少症またはグレード3の血小板減少症の数
時間枠:30日後の索引手順
|
30日後の索引手順
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
研究完了までに登録された最初の患者からの治療関連の有害事象および治療関連の重篤な有害事象(事前定義された制限毒性を含まない)の割合。
時間枠:6か月後の索引手順による登録
|
6か月後の索引手順による登録
|
|
|
研究完了までに登録された最初の患者からの客観的奏効率* (ORR)
時間枠:6か月後の索引手順による登録
|
6か月後の索引手順による登録
|
|
|
研究完了までに登録された最初の患者からの無増悪生存率* (PFS)
時間枠:6か月後の索引手順による登録
|
6か月後の索引手順による登録
|
|
|
研究完了までに登録された最初の患者からの全生存期間 (OS)
時間枠:6か月後の索引手順による登録
|
6か月後の索引手順による登録
|
|
|
Therasphere GBMの技術的成功/実現可能性 - デバイスで治療されたすべての患者の灌流量に投影された放射線吸収用量(+/- 20%)を供給する能力。事前スクリーニングからデバイス後の配達PET-CT/MRIまで評価されます。
時間枠:デバイス後の配達後のPET-CT/MRIの事前スクリーニング。
|
デバイス後の配達後のPET-CT/MRIの事前スクリーニング。
|
|
|
Change in post-treatment neurological function as assessed by the National Institute of Health Stroke Scale (NIHSS).
時間枠:Enrollment through 6 months post index procedure
|
The NIHSS is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. |
Enrollment through 6 months post index procedure
|
|
Change in post-treatment neurological function as assessed by the modified Rankin Scale (mRS).
時間枠:Enrollment through 6 months post index procedure
|
The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability on a scale from 0 (no symptoms at all) to 6 (death). |
Enrollment through 6 months post index procedure
|
協力者と研究者
捜査官
- 主任研究者:Riad Salem, M.D.、Northwestern University
- 主任研究者:Roger Stupp, M.D.、Northwestern University
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- S2478
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。